A clinical trial reported progress on using donor-derived regulatory dendritic cells (DCreg) to modulate immune response after living-donor liver transplantation while enabling earlier withdrawal of conventional immunosuppression. The strategy combines DCreg infusion with early reduction of standard immunosuppressive therapy in transplant recipients. The study centers on achieving immune tolerance-like effects by reshaping the post-transplant immune environment, with DCreg aiming to promote regulatory pathways rather than broad immune suppression. The trial is positioned as a step toward reducing long-term exposure-related toxicities tied to ongoing immunosuppressant use. From a translational standpoint, the approach targets one of the highest-friction elements in liver transplantation: balancing rejection risk against immunosuppression adverse effects. If results continue to hold in larger follow-up, it could influence future standards for immune management after transplant. The sector implication is that cell-based immunotherapies are moving beyond oncology and infectious disease into more operationally complex transplant settings, where efficacy must be paired with safety and predictable dosing timelines.